Altea Therapeutics has developed an advanced drug delivery system that allows a wide variety of drugs and vaccines across the skin. This breakthrough should improve the efficacy, safety and compliance of drugs and vaccines.

Co-investors: Domain Associates, Venrock Associates, vSpring Capital

www.alteatherapeutics.com

 

Cameron Health is developing a novel implantable cardioverter defibrillator that is easier to implant and has no intravenous leads.

Co-investors: Three Arch Partners, Versant Ventures, Delphi Ventures

www.cameronhealth.com

Cardiocore Lab, Inc. advances the quality and speed of clinical trials by providing the world’s finest cardiac testing services. Centralized services include ECG analysis, Holter monitoring, protocol design and statistical analysis.

Co-investors: Caxton Health

www.cardiocorelab.com

CardioMEMS, Inc. is a medical device company that develops wireless medical pressure sensors. The technology platform is initially designed to improve the management of severe cardiovascular diseases such as heart failure and aneurysms.

Co-investors: Boston Millenia, Arcapita Ventures, Foundation Medical, Easton Capital, Medtronic

www.cardiomems.com

    Ception Therapeutics, Inc. is an emerging biopharmaceutical company discovering and developing novel biologic and small-molecule agents to address unmet medical needs.  The company has late-stage biologic anti-inflammatory programs, a small molecule anti-TNF program and several other discovery programs.

Acquired by Cephalon

Co-investors: Essex Woodlands, Investor Growth Capital, MDS, New Science Ventures, Third Point 

www.ceptiontx.com

Concerro is an IT company focused on providing flexible workforce management solutions for the healthcare industry.  The company’s lead offering is a software system that enables facilities to create and manage an internal registry for nurses and other clinical staff, providing significant ROI for the facilities and flexibility and increased income for the staff. 

Co-investors: Kaiser Ventures, Himalaya Capital, RK Ventures

www.concerro.com

    Conor Medsystems is a medical device company that develops stents and other medical devices as delivery platforms for controlled local delivery of a wide variety of therapeutic agents. Its proprietary technologies enable the delivery of multiple drugs or biotech compounds to various sites in the body.

NASD:  CONR

Acquired by Johnson & Johnson

Co-investors: Easton Capital,  Highland Capital, Maverick Capital

www.conormed.com

 

Interlace Medical is a medical device company developing minimally invasive treatment options in the field of women's health.

Co-investors:  New Leaf, Spray, Baird, HLM, H&Q

www.interlacemedical.com

    Mako Surgical is a medical device company that is developing advanced technologies and procedures for the rapidly emerging orthopedic minimally invasive total joint market.

NASD: MAKO

Co-investors: MDS Capital, Skyline, Montreux, Alta, Exxel Group

www.makosurgical.com

    Redpoint Bio is a biotechnology company that has made breakthroughs in the science of taste: the elimination of the perception of bitterness and the enhancement of the sweetness of natural sugar. These breakthroughs can potentially be used extensively in the pharmaceutical and food and beverage industries. The product line will consist of natural compounds that will have their desired effects when mixed with the target products.

OTCBB: RPBC

Co-investors: Cargill Ventures, NJTC Ventures, SR One

www.redpointbio.com

    TherOx developed its SuperSaturated Oxygen Therapy to treat ischemic tissues and conditions. Using the TherOx technology, hyperbaric levels of oxygen can be delivered to the heart to salvage tissue affected by acute myocardial infarction. This is the first of many applications for TherOx’s technology platform.

Co-investors: Kleiner Perkins, DAG Ventures, Integral Capital, New Science Ventures, Wasatch Ventures

www.therox.com

   

TransMolecular is a biotechnology company committed to discovering, developing and commercializing novel and proprietary drugs to diagnose and treat cancer and pain. TransMolecular is developing a targeted approach to treating cancer using synthetic versions of peptides isolated from natural products. The company's lead compound, targeting a deadly form of brain cancer, is in clinical trials.

Co-investors:   Easton Capital, MDS Capital, Tullis Dickerson, TVM Capital 

www.transmolecular.com

  © Aperture Venture Partners, LLC 2010. All rights reserved.